Boland Elaine G, Mulvey Matthew R, Bennett Michael I
aQueen's Centre for Oncology and Haematology, Hull and East Yorkshire Hospitals NHS Trust and Hull York Medical School, University of Hull, Hull bAcademic Unit of Palliative Care, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Curr Opin Support Palliat Care. 2015 Jun;9(2):112-5. doi: 10.1097/SPC.0000000000000136.
Neuropathic pain can affect up to 40% in patients with cancer, which could be related to the tumour, treatment or comorbid diseases. Effective assessment to diagnose neuropathic pain is crucial in order to choose the right treatment.
There is to date no systematic classification system; the Neuropathic Pain Special Interest Group of the International Association for the Study of Pain developed a neuropathic pain grading system intended to be used for both clinical and research purposes, and a recent review describes a step-by-step process for applying the grading system in a clinical setting for cancer pain.
We have combined these recommendations to outline a clinically relevant process to classify neuropathic pain in patients with cancer.
神经性疼痛在癌症患者中的发生率可达40%，这可能与肿瘤、治疗或合并症有关。为了选择正确的治疗方法，有效的神经性疼痛评估诊断至关重要。
迄今为止尚无系统的分类系统；国际疼痛研究协会的神经性疼痛特别兴趣小组制定了一个神经性疼痛分级系统，旨在用于临床和研究目的，最近的一篇综述描述了在临床环境中对癌症疼痛应用该分级系统的逐步过程。
我们结合了这些建议，概述了一个对癌症患者神经性疼痛进行分类的临床相关过程。
